Medarex, Ciba Form Partnership

August 1, 1995

ANNANDALE, NJ--Medarex, Inc. and Ciba-Geigy, Ltd. have entered into an alliance for developing and marketing Medarex's MDX-210 Bispecific product. Medarex will be primarily responsible for development through phase II trials, and Ciba will be responsible for phase III trials, regulatory approvals, and commercial launch.

ANNANDALE, NJ--Medarex, Inc. and Ciba-Geigy, Ltd. have enteredinto an alliance for developing and marketing Medarex's MDX-210Bispecific product. Medarex will be primarily responsible fordevelopment through phase II trials, and Ciba will be responsiblefor phase III trials, regulatory approvals, and commercial launch.

MDX-210 is designed to induce tumor cell killing by simultaneouslybinding to the HER-2 protein on the cancer cell surface and toa key receptor on immune system killer cells. The product is currentlyin clinical trials for the treatment of breast, ovarian, prostate,and other tumors.